ADAM9 and Neoplasm of the pancreas: This study was designed to further validate the significance of ADAM9 overexpression in PDACs by comparing the results with those obtained in pancreatic tumours other than PDACs, and by correlating the immunohistochemical labelling of the individual PDACs with the survival of the patients.